Survival Outcomes and Treatment Strategies in Primary Thyroid Lymphoma: A Population-Based Study of 401 Cases from the Tokyo Cancer Registry
Authors' conclusion
Disease-specific mortality was highest in the first two years, particularly the first six months, highlighting this as a critical management period and the importance of timely treatment. Despite recent treatment advances that have improved the overall prognosis and reduced prognostic differences among disease stages, age at diagnosis and histological subtype remain key OS and DSS determinants, with older patients and DLBCL patients experiencing poorer outcomes.
Study context
- Population
- Patients with primary thyroid lymphoma (PTL) registered 2012–2020 in the Tokyo Cancer Registry, Japan
- Participants
- 401 patients
- Outcome
- Survival outcomes:
- OS
- Disease-specific survival
- Follow-up
- Median 3.3 years (IQR 1.2-5.5 years)
Methodological detailsTokyo Cancer Registry
- Tokyo Cancer Registry
Main finding
As reported in the abstract
- Disease-specific mortality concentrated in the first two years postdiagnosis, particularly the initial six months
- Advanced age (≥80 years) and diffuse large B-cell lymphoma (DLBCL) associated with poorer overall survival (OS) and disease-specific survival (DSS)
- Current lymphoma staging systems do not significantly differentiate survival outcomes
- Favorable outcomes with localized treatments, including curative surgery alone, for stage IE PTL
Observational data: associations, not effects.
Original publication
Survival Outcomes and Treatment Strategies in Primary Thyroid Lymphoma: A Population-Based Study of 401 Cases from the Tokyo Cancer Registry. Thyroid. Published 3 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →